Nevro Corp. (NYSE:NVRO) – Stock analysts at Leerink Swann lowered their Q1 2019 earnings per share estimates for Nevro in a research note issued to investors on Thursday. Leerink Swann analyst D. Antalffy now expects that the medical equipment provider will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.03. Leerink Swann currently has a “Outperform” rating and a $110.00 target price on the stock. Leerink Swann also issued estimates for Nevro’s Q2 2019 earnings at $0.09 EPS and FY2020 earnings at $0.89 EPS.

A number of other equities research analysts have also recently issued reports on NVRO. Morgan Stanley upped their price objective on shares of Nevro from $87.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, August 8th. Northland Securities reiterated a “buy” rating and issued a $96.00 price objective on shares of Nevro in a report on Tuesday, August 8th. Zacks Investment Research cut shares of Nevro from a “buy” rating to a “hold” rating in a report on Friday, August 11th. BMO Capital Markets reiterated a “buy” rating and issued a $106.00 price objective on shares of Nevro in a report on Friday, September 1st. Finally, BidaskClub upgraded shares of Nevro from a “sell” rating to a “hold” rating in a report on Saturday, October 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $100.00.

Shares of Nevro (NYSE NVRO) traded down $2.15 during trading hours on Monday, reaching $66.83. 643,475 shares of the company were exchanged, compared to its average volume of 509,136. Nevro has a 12-month low of $65.82 and a 12-month high of $99.63. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.02. The firm had revenue of $82.26 million during the quarter, compared to analysts’ expectations of $80.50 million. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. Nevro’s revenue for the quarter was up 35.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.14) earnings per share.

Several institutional investors and hedge funds have recently made changes to their positions in NVRO. Ameritas Investment Partners Inc. raised its position in shares of Nevro by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after buying an additional 358 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Nevro during the second quarter valued at about $190,000. US Bancorp DE raised its position in shares of Nevro by 412.4% during the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 2,099 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Nevro during the third quarter valued at about $211,000. Finally, Prudential Financial Inc. raised its position in Nevro by 13.8% in the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after purchasing an additional 350 shares in the last quarter.

In other news, Director Wilfred E. Jaeger sold 16,467 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $90.19, for a total transaction of $1,485,158.73. Following the completion of the transaction, the director now owns 1,518 shares of the company’s stock, valued at $136,908.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total transaction of $525,770.00. The disclosure for this sale can be found here. Insiders have sold 63,467 shares of company stock valued at $5,576,679 over the last 90 days. Corporate insiders own 9.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/06/q1-2019-eps-estimates-for-nevro-corp-nvro-lowered-by-analyst.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.